Download PDF
Onkologie up2date 2020; 2(02): 107-118
DOI: 10.1055/a-1132-0051
Tumoren der Atemwege
Georg Thieme Verlag KG Stuttgart · New York

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Christine Langer
,
Claus Wittekindt
,
Gregor Wolf
Further Information

Publication History

Publication Date:
20 May 2020 (online)

    Permissions and Reprints All articles of this category

Die rezidivierende respiratorische Papillomatose (RRP) – ausgelöst durch das humane Papillomavirus (HPV) – ist durch warzenartige Veränderungen der Atemwege gekennzeichnet. Der klinische Verlauf ist variabel, die Diagnosestellung erfolgt nicht selten wesentlich später als der Symptombeginn, insbesondere bei Kindern. Die Behandlung wird individuell festgelegt und umfasst meist Operationen zur Tumorkontrolle und zum Erhalt der Stimmfunktion.
Kernaussagen

  • Die rezidivierende respiratorische Papillomatose (RRP) ist eine durch humane Papillomaviren verursachte Erkrankung, deren Infektionsweg nicht zweifelsfrei geklärt ist.

  • Man unterscheidet abhängig vom Lebensalter der Erstmanifestation die juvenile (JORRP) von der adulten (AORRP) Form, wobei erstere hochgradigere Verläufe aufweist.

  • Der klinische Verlauf der Erkrankung ist sehr variabel und abhängig vom nachgewiesenen Virustyp.

  • Grundlegendes Therapieprinzip ist die schonende chirurgische Abtragung zur Kontrolle der Erkrankung sowie zum funktionellen Erhalt des Atem- und Schluckwegs. Radikal-chirurgische Ansätze sind aufgrund der Viruspersistenz im umgebenden Gewebe nicht angezeigt.

  • Eine medikamentös-adjuvante Therapie ist insbesondere bei schwergradigen Verläufen mit hoher Therapiefrequenz indiziert. Hierfür stehen verschiedene Medikamente zur Verfügung, welche jedoch weder für die Indikation zugelassen noch in kontrollierten Studien untersucht worden sind. Dennoch existieren hoffnungsvolle klinisch-experimentelle Untersuchungen, insbesondere für die Präparate Cidofovir und Bevacizumab.

 

  • Literatur

  • 1 Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118: 450-454
    CrossrefPubMedGoogle Scholar
  • 2 Gallagher TQ, Derkay CS. Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion. Expert Opin Pharmacother 2009; 10: 645-655
    CrossrefPubMedGoogle Scholar
  • 3 Lindeberg H, Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965–1984. Clin Otolaryngol Allied Sci 1990; 15: 125-131
    CrossrefPubMedGoogle Scholar
  • 4 Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118: 1236-1247
    CrossrefPubMedGoogle Scholar
  • 5 Buchinsky FJ, Donfack J. Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS One 2008; 28: e2263
    Google Scholar
  • 6 Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125: 743-748
    CrossrefPubMedGoogle Scholar
  • 7 Munoz N, Bosch FX, de Sanjosé S. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-552
    CrossrefPubMedGoogle Scholar
  • 8 Rabah R, Lancaster WD, Thomas R. et al. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001; 4: 68-72
    CrossrefPubMedGoogle Scholar
  • 9 Kashima HK, Kessis T, Mounts P. et al. Polymerase chain reaction identification of human papillomavirus DNA in CO2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991; 104: 191-195
    CrossrefPubMedGoogle Scholar
  • 10 Kashima H, Wu TC, Mounts P. et al. Carcinoma ex-papilloma: histologic and virologic studies in whole-organ sections of the larynx. Laryngoscope 1988; 98 (6 Pt 1): 619-624
    PubMedGoogle Scholar
  • 11 Yoshpe NS. Oral and laryngeal papilloma: a pediatric manifestation of sexually transmitted disease?. Int J Pediatr Otorhinolaryngol 1995; 31: 77-83
    CrossrefPubMedGoogle Scholar
  • 12 Fredericks BD, Balkin A, Daniel HW. et al. Transmission of human papillomaviruses from mother to child. Aust N Z J Obstet Gynaecol 1993; 33: 30-32
    CrossrefPubMedGoogle Scholar
  • 13 McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005; 69: 597-605
    CrossrefPubMedGoogle Scholar
  • 14 Shah KV, Stern WF, Shah FK. et al. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis 1998; 17: 372-376
    CrossrefPubMedGoogle Scholar
  • 15 Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118: 450-454
    CrossrefPubMedGoogle Scholar
  • 16 Kashima H, Shah F, Lyles A. A comparison of risk factors in juvenile-onset and adult-onset respiratory papillomas. Laryngoscope 1992; 102: 9-13
    PubMedGoogle Scholar
  • 17 Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001; 111: 57-69
    CrossrefPubMedGoogle Scholar
  • 18 Reeves WC, Ruparelia SS, Swanson KI. et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982
    CrossrefPubMedGoogle Scholar
  • 19 Silver RD, Rimell FL, Adams GL. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2003; 129: 622-629
    PubMedGoogle Scholar
  • 20 Abramson AL, Nouri M, Mullooly V. et al. Latent Human Papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004; 72: 473-477
    CrossrefPubMedGoogle Scholar
  • 21 Leunig A, Betz CS, Mehlmann M. A pilot series demonstrating fluorescence staining of laryngeal papilloma using 5-aminolevulinic acid. Laryngoscope 2000; 110: 1783-1785
    CrossrefPubMedGoogle Scholar
  • 22 Derkay CS, Hester RP, Burke P. et al. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2004; 68: 1493-1498
    CrossrefPubMedGoogle Scholar
  • 23 Reeves WC, Ruparelia SS, Swanson KI. et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982
    CrossrefPubMedGoogle Scholar
  • 24 Tasca RA, McCormick M, Clarke RW. British Association of Paediatric Otorhinolaryngology members experience with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2006; 70: 1183-1187
    CrossrefPubMedGoogle Scholar
  • 25 Pasquale K, Wiatrak B, Woolley A. et al. Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003; 113: 139-143
    CrossrefPubMedGoogle Scholar
  • 26 Schraff S, Derkay CS, Burke B. et al. American Society of Pediatric Otolaryngology membersʼ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004; 130: 1039-1042
    CrossrefPubMedGoogle Scholar
  • 27 Andratschke A, Betz C, Leunig A. Larynxpapillomatose, Ätiologie, Diagnostik und Therapie. HNO 2008; 56: 1190-1196
    CrossrefPubMedGoogle Scholar
  • 28 Johnson K, Derkay C. Palliative aspects of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2009; 42: 57-70
    CrossrefPubMedGoogle Scholar
  • 29 Kashima HK, Kessis T, Mounts P. et al. Polymerase chain reaction identification of human papillomavirus DNA in CO2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991; 104: 191-195
    CrossrefPubMedGoogle Scholar
  • 30 Hartnick CJ, Boseley ME, Franco RA. et al. Efficacy of treating children with anterior commissure and true vocal fold respiratory papilloma with the 585-nm pulsed-dye laser. Arch Otolaryngol Head Neck Surg 2007; 133: 127-130
    CrossrefPubMedGoogle Scholar
  • 31 Carifi M, Napolitano D, Morandi M. et al. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015; 11: 731-738
    PubMedGoogle Scholar
  • 32 Healy GB, Gelber RD, Trowbridge AL. et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988; 319: 401-407
    CrossrefPubMedGoogle Scholar
  • 33 Maunsell R, Bellomo-Brandao AM. Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child. A case report. Sao Paolo Med J 2018; 136: 376-381
    Google Scholar
  • 34 Holland B, Koufman J, Postma G. et al. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002; 112: 1926-1929
    CrossrefPubMedGoogle Scholar
  • 35 Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004; 18: 248-253
    CrossrefPubMedGoogle Scholar
  • 36 Abramson AL, Shikowitz MJ, Mullooly VM. et al. Variable light-dose effect on photodynamic therapy for laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1994; 120: 852-855
    CrossrefPubMedGoogle Scholar
  • 37 Shikowitz MJ, Abramson AL, Steinberg BM. et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004; 131: 99-105
    Google Scholar
  • 38 Pudzuhn A, Welzel C, Bloching M. et al. Intralesional cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol 2007; 264: 63-70
    CrossrefPubMedGoogle Scholar
  • 39 Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003; 113: 1583-1587
    CrossrefPubMedGoogle Scholar
  • 40 Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English language literature. Otolaryngol Head Neck Surg 2007; 136: 863-869
    CrossrefPubMedGoogle Scholar
  • 41 Bedard J, May S, Lis M. et al. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrob Agents Chemother 1999; 43: 557-567
    CrossrefPubMedGoogle Scholar
  • 42 Nawka T. Larynxpapillomatose. Laryngorhinootologie 2018; 97: 670-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Best SR, Mohr M, Zur KB. Systemic bevcizumab for recurrent respiratory papillomatosis: A national survey. Laryngoscope 2017; 127: 2225-2229
    CrossrefPubMedGoogle Scholar
  • 44 Sidell DR, Nassar M, Cotton RT. et al. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2014; 123: 214-221
    CrossrefPubMedGoogle Scholar
  • 45 Yiu Y, Fayson S, Smith H. et al. Implementation of Routine HPV Vaccination in the Management of Recurrent respiratory Papillomatosis. Ann Otol Rhinol Laryngol 2019; 128: 309-315
    CrossrefPubMedGoogle Scholar
  • 46 Papaioannou VA, Arens C. Behandlungsergebnisse der rezidivierenden respiratorischen Papillomatose mit Gardasil. Laryngorhinootologie 2018; 97 (02) 213
    Google Scholar
  • 47 Papaioannou VA, Lux A, Zimmermann S. et al. Behandlungsergebnisse bei rezidivierender respiratorischer Papillomatose – retrospektive Analyse juvenile und adulter Fälle. HNO 2017; 65: 923-932
    CrossrefPubMedGoogle Scholar
  • 48 Hall MT, Simms KT, Lew JB. et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 2019; 4: e19-e27
    PubMedGoogle Scholar
  • 49 Novakovic D, Cheng ATL, Zurynski Y. et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis 2018; 217: 208-212
    CrossrefPubMedGoogle Scholar